Induced pluripotent stem cells as a disease model for studying inherited arrhythmias

Promises and hurdles

Kathy O. Lui, Maxine W. Stachel, Deborah Lieu, Ronald A. Li, Lei Bu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Cardiac ion channel mutations can lead to alterations of action potential and/or conduction properties, and consequently, arrhythmias. Although sudden cardiac death is a common manifestation of inherited arrhythmias, many aspects of the underlying mechanisms remain undefined. In addition to their potential for cell-based therapies, patient-specific induced pluripotent stem cells (iPSCs) also offer an expandable source of human cardiomyocytes for disease modeling, high-throughput drug screening and cardiotoxicity testing. Here, we review current efforts of using iPSC to model monogenetic arrhythmic diseases and discuss the associated challenges.

Original languageEnglish (US)
JournalDrug Discovery Today: Disease Models
Volume9
Issue number4
DOIs
StatePublished - Dec 2012

Fingerprint

Induced Pluripotent Stem Cells
Cardiac Arrhythmias
Preclinical Drug Evaluations
Sudden Cardiac Death
Cell- and Tissue-Based Therapy
Ion Channels
Cardiac Myocytes
Action Potentials
Mutation
Cardiotoxicity

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine

Cite this

Induced pluripotent stem cells as a disease model for studying inherited arrhythmias : Promises and hurdles. / Lui, Kathy O.; Stachel, Maxine W.; Lieu, Deborah; Li, Ronald A.; Bu, Lei.

In: Drug Discovery Today: Disease Models, Vol. 9, No. 4, 12.2012.

Research output: Contribution to journalArticle

@article{1ea73321db424ce8a92473b07523fba6,
title = "Induced pluripotent stem cells as a disease model for studying inherited arrhythmias: Promises and hurdles",
abstract = "Cardiac ion channel mutations can lead to alterations of action potential and/or conduction properties, and consequently, arrhythmias. Although sudden cardiac death is a common manifestation of inherited arrhythmias, many aspects of the underlying mechanisms remain undefined. In addition to their potential for cell-based therapies, patient-specific induced pluripotent stem cells (iPSCs) also offer an expandable source of human cardiomyocytes for disease modeling, high-throughput drug screening and cardiotoxicity testing. Here, we review current efforts of using iPSC to model monogenetic arrhythmic diseases and discuss the associated challenges.",
author = "Lui, {Kathy O.} and Stachel, {Maxine W.} and Deborah Lieu and Li, {Ronald A.} and Lei Bu",
year = "2012",
month = "12",
doi = "10.1016/j.ddmod.2012.09.001",
language = "English (US)",
volume = "9",
journal = "Drug Discovery Today: Disease Models",
issn = "1740-6757",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Induced pluripotent stem cells as a disease model for studying inherited arrhythmias

T2 - Promises and hurdles

AU - Lui, Kathy O.

AU - Stachel, Maxine W.

AU - Lieu, Deborah

AU - Li, Ronald A.

AU - Bu, Lei

PY - 2012/12

Y1 - 2012/12

N2 - Cardiac ion channel mutations can lead to alterations of action potential and/or conduction properties, and consequently, arrhythmias. Although sudden cardiac death is a common manifestation of inherited arrhythmias, many aspects of the underlying mechanisms remain undefined. In addition to their potential for cell-based therapies, patient-specific induced pluripotent stem cells (iPSCs) also offer an expandable source of human cardiomyocytes for disease modeling, high-throughput drug screening and cardiotoxicity testing. Here, we review current efforts of using iPSC to model monogenetic arrhythmic diseases and discuss the associated challenges.

AB - Cardiac ion channel mutations can lead to alterations of action potential and/or conduction properties, and consequently, arrhythmias. Although sudden cardiac death is a common manifestation of inherited arrhythmias, many aspects of the underlying mechanisms remain undefined. In addition to their potential for cell-based therapies, patient-specific induced pluripotent stem cells (iPSCs) also offer an expandable source of human cardiomyocytes for disease modeling, high-throughput drug screening and cardiotoxicity testing. Here, we review current efforts of using iPSC to model monogenetic arrhythmic diseases and discuss the associated challenges.

UR - http://www.scopus.com/inward/record.url?scp=84876694169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876694169&partnerID=8YFLogxK

U2 - 10.1016/j.ddmod.2012.09.001

DO - 10.1016/j.ddmod.2012.09.001

M3 - Article

VL - 9

JO - Drug Discovery Today: Disease Models

JF - Drug Discovery Today: Disease Models

SN - 1740-6757

IS - 4

ER -